Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Summary

The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.

Timeline

Start

2003-12

Primary completion

2004-08

Completion

2004-09

Drugs

Indications